These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 16908731)

  • 21. Neurologic indications for therapeutic plasma exchange: 2011 update.
    Gwathmey K; Balogun RA; Burns T
    J Clin Apher; 2012; 27(3):138-45. PubMed ID: 22522566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Which patients should be treated with plasma exchange? Indications for plasma exchange therapy].
    Cala S
    Lijec Vjesn; 1996; 118(11-12):286-90. PubMed ID: 9213718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Plasma exchange therapy (plasmapheresis/plasmafiltration). II. Indications and complications].
    Quietzsch D; Liebert A; Zimmermann S
    Z Gesamte Inn Med; 1984 Oct; 39(20):493-500. PubMed ID: 6549091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence-based review of therapeutic plasma exchange in neurological disorders.
    Chhibber V; Weinstein R
    Semin Dial; 2012; 25(2):132-9. PubMed ID: 22277020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasmapheresis in neurological diseases. Experience in 140 procedures in 47 patients].
    Nogales-Gaete J; Valenzuela D; Liendo F; Vidal P; Gil G; Sáez D
    Rev Med Chil; 2004 Mar; 132(3):295-8. PubMed ID: 15376565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmapheresis for neurological disorders.
    Schröder A; Linker RA; Gold R
    Expert Rev Neurother; 2009 Sep; 9(9):1331-9. PubMed ID: 19769448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guidelines for the treatment of autoimmune neuromuscular transmission disorders.
    Skeie GO; Apostolski S; Evoli A; Gilhus NE; Hart IK; Harms L; Hilton-Jones D; Melms A; Verschuuren J; Horge HW
    Eur J Neurol; 2006 Jul; 13(7):691-9. PubMed ID: 16834699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic plasma exchange in neurology: 2012.
    Cortese I; Cornblath DR
    J Clin Apher; 2013 Feb; 28(1):16-9. PubMed ID: 23420591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmapheresis in the critically ill patient.
    Berlot G; Tomasini A; Silvestri L; Gullo A
    Kidney Int Suppl; 1998 May; 66():S178-81. PubMed ID: 9573599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on the evaluation and therapy of autoimmune neuromuscular junction disorders.
    Katz J; Barohn RJ
    Phys Med Rehabil Clin N Am; 2001 May; 12(2):381-97. PubMed ID: 11345014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromuscular disorders in clinical practice: case studies.
    Bhatt JR; Pascuzzi RM
    Neurol Clin; 2006 May; 24(2):233-65. PubMed ID: 16684631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders.
    van der Meché FG; van Doorn PA
    Muscle Nerve; 1997 Feb; 20(2):136-47. PubMed ID: 9040650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Plasmapheresis in intensive therapy unit].
    Szczeklik W; Mitka I; Nowak I; Seczyńiska B; Sega A; Wegrzyn W; Królikowski W
    Anestezjol Intens Ter; 2010; 42(2):100-6. PubMed ID: 21413437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A diagnostic and management dilemma: combined paraneoplastic myasthenia gravis and Lambert-Eaton myasthenic syndrome presenting as acute respiratory failure.
    Roohi F; Smith PR; Bergman M; Baig MA; Sclar G
    Neurologist; 2006 Nov; 12(6):322-6. PubMed ID: 17122730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibody testing.
    Pourmand R
    Neurol Clin; 2004 Aug; 22(3):703-17, vii. PubMed ID: 15207881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Facilities, selection, outcome measurement, and limitations of therapeutic plasma exchange for neuroimmunological disorders: The South East Asian survey study.
    Rattanathamsakul N; Siritho S; Viswanathan S; Hiew FL; Apiwattanakul M; Tan K; Thirugnanam UN; Yeo T; Quek AML; Estiasari R; Remli R; Aye SMM; Ohnmar O; Hoang NTT; Pasco PM
    J Clin Apher; 2023 Aug; 38(4):437-446. PubMed ID: 36896493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromuscular disorders in critical illness.
    Zochodne DW; Bolton CF
    Baillieres Clin Neurol; 1996 Oct; 5(3):645-71. PubMed ID: 9117080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of therapeutic plasma exchange for pediatric neurological diseases.
    Ipe TS; Meyer EK; Sanford KW; Joshi SK; Wong ECC; Raval JS
    J Clin Apher; 2021 Feb; 36(1):161-176. PubMed ID: 33063869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The utility of therapeutic plasmapheresis for neurological disorders.
    Natl Inst Health Consens Dev Conf Consens Statement; 1986; 6(4):1-7. PubMed ID: 3537747
    [No Abstract]   [Full Text] [Related]  

  • 40. Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies.
    Townson K; Boffey J; Nicholl D; Veitch J; Bundle D; Zhang P; Samain E; Antoine T; Bernardi A; Arosio D; Sonnino S; Isaacs N; Willison HJ
    Glycobiology; 2007 Mar; 17(3):294-303. PubMed ID: 17145744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.